Filtered By:
Specialty: Endocrinology
Condition: Diabetes
Drug: Januvia

This page shows you your search results in order of relevance.

Order by Relevance | Date

Total 18 results found since Jan 2013.

Regional, age, and sex differences in baseline characteristics of patients enrolled in the Trial Evaluating Cardiovascular Outcomes with Sitagliptin (TECOS)
ConclusionCV risk factors of TECOS participants are reasonably controlled on average, but differences in CV risk management according to region, sex, and history of prior disease exist. This diversity will enhance generalizability of the trial results.
Source: Diabetes, Obesity and Metabolism - January 20, 2015 Category: Endocrinology Authors: M. A. Bethel, J.B. Green, J. Milton, A. Tajar, S. S. Engel, R. M. Califf, R. R. Holman, Tags: ORIGINAL ARTICLE Source Type: research

Regional, age and sex differences in baseline characteristics of patients enrolled in the Trial Evaluating Cardiovascular Outcomes with Sitagliptin (TECOS)
ConclusionThe CV risk factors of participants in TECOS are reasonably controlled, but differences in CV risk management according to region, sex and history of disease exist. This diversity will enhance the generalizability of the trial results.
Source: Diabetes, Obesity and Metabolism - February 13, 2015 Category: Endocrinology Authors: M. A. Bethel, J. B. Green, J. Milton, A. Tajar, S. S. Engel, R. M. Califf, R. R. Holman, Tags: ORIGINAL ARTICLE Source Type: research

Real-World Data on the Incidence of Macrovascular Complications in Japanese Patients with Type 2 Diabetes: The Sitagliptin Registration Type 2 Diabetes-Juntendo Collaborating Project
ConclusionThe extended SPIRITS-J study demonstrated that optimal comprehensive management in patients with type 2 diabetes according to the recent practice guidelines has succeeded in preventing macrovascular complications in Japan. This study suggests that more intensive LDL-C-lowering therapy is important for further prevention of macrovascular complications even in Japanese patients with type 2 diabetes (UMIN 000004121).
Source: Diabetes Therapy - April 25, 2019 Category: Endocrinology Source Type: research

All‐cause mortality and cardiovascular effects associated with the DPPIV‐inhibitor sitagliptin compared with metformin, a retrospective cohort study on the Danish population
ConclusionIn a retrospective analysis, sitagliptin monotherapy compared with metformin monotherapy was not associated with any statistical significant increased risk of all‐cause mortality or the composite endpoint, but was associated with an increased likelihood of changing glucose‐lowering treatment.
Source: Diabetes, Obesity and Metabolism - August 21, 2013 Category: Endocrinology Authors: Nikolai Madrid Scheller, Ulrik Madvig Mogensen, Charlotte Andersson, Allan Vaag, Christian Torp‐Pedersen Tags: Original Article Source Type: research

All‐cause mortality and cardiovascular effects associated with the DPP‐IV inhibitor sitagliptin compared with metformin, a retrospective cohort study on the Danish population
ConclusionIn a retrospective analysis, sitagliptin monotherapy compared with metformin monotherapy was not associated with any statistical significant increased risk of all‐cause mortality or the composite endpoint, but was associated with an increased likelihood of changing glucose‐lowering treatment.
Source: Diabetes, Obesity and Metabolism - September 10, 2013 Category: Endocrinology Authors: N. M. Scheller, U. M. Mogensen, C. Andersson, A. Vaag, C. Torp‐Pedersen Tags: ORIGINAL ARTICLE Source Type: research

Cardiovascular safety of albiglutide in the Harmony programme: a meta-analysis
Publication date: Available online 11 August 2015 Source:The Lancet Diabetes & Endocrinology Author(s): Miles Fisher, Mark C Petrie, Philip D Ambery, Jill Donaldson, John J V McMurray, June Ye Background Albiglutide is a glucagon-like peptide-1 receptor agonist, a new class of drugs used to treat type 2 diabetes. We did a prospective meta-analysis of the cardiovascular safety of albiglutide as stipulated by the US Food and Drug Administration recommendations for the assessment of new treatments for diabetes. Methods We did a meta-analysis of eight phase 3 trials and one phase 2b trial in which patients wer...
Source: The Lancet Diabetes and Endocrinology - August 12, 2015 Category: Endocrinology Source Type: research

Insights From Cardiovascular Outcome Trials with Novel Antidiabetes Agents: What Have We Learned? An Industry Perspective
Abstract Owing to the close association of cardiovascular (CV) disease with type 2 diabetes and the uncertainty surrounding the CV safety of antidiabetes agents, in 2008 the Food and Drug Administration issued guidance for the demonstration of CV safety for new antidiabetes drugs. Recently the results from CV outcomes trials of three dipeptidyl peptidase-4 (DPP-4) inhibitors and a glucagon-like peptide-1 receptor agonist have been reported. The Saxagliptin Assessment of Vascular Outcomes Recorded in Patients with Diabetes Mellitus (SAVOR) trial, the Examination of Cardiovascular Outcomes with Alogliptin versus St...
Source: Current Diabetes Reports - September 14, 2015 Category: Endocrinology Source Type: research

Association of Sitagliptin with cardiovascular outcome in diabetic patients: a nationwide cohort study
Conclusions The results showed a favorable outcome of Sitagliptin as a class on lowering CVD incidence in patients with type 2 diabetes.
Source: Acta Diabetologica - December 21, 2015 Category: Endocrinology Source Type: research

Liraglutide improves cardiac function in patients with type 2 diabetes and chronic heart failure
ConclusionsThese data provide evidence that treatment with liraglutide is associated with improvement of cardiac function and functional capacity in failing post-ischemic type-2 diabetes mellitus patients.
Source: Endocrine - November 8, 2016 Category: Endocrinology Source Type: research

Integration of recent evidence into management of patients with atherosclerotic cardiovascular disease and type 2 diabetes
Publication date: Available online 26 January 2017 Source:The Lancet Diabetes & Endocrinology Author(s): Eberhard Standl, Oliver Schnell, Darren K McGuire, Antonio Ceriello, Lars Rydén Cardiovascular outcome trials of antihyperglycaemic drugs and non-statin LDL-cholesterol-lowering drugs in patients with type 2 diabetes who have, or who are at high risk of, atherosclerotic cardiovascular disease have provided new evidence that has substantially affected the management of cardiovascular risk in these patients. On the basis of proven cardiovascular and renal benefit, the antihyperglycaemic drugs empagliflozin, lira...
Source: The Lancet Diabetes and Endocrinology - January 25, 2017 Category: Endocrinology Source Type: research

Assessing the Safety of Sitagliptin in Older Participants in the Trial Evaluating Cardiovascular Outcomes with Sitagliptin (TECOS)
CONCLUSIONS Among older patients with well-controlled type 2 diabetes and cardiovascular disease, sitagliptin had neutral effects on cardiovascular risk and raised no significant safety concerns.
Source: Diabetes Care - March 20, 2017 Category: Endocrinology Authors: Bethel, M. A.; Engel, S. S.; Green, J. B.; Huang, Z.; Josse, R. G.; Kaufman, K. D.; Standl, E.; Suryawanshi, S.; Van de Werf, F.; McGuire, D. K.; Peterson, E. D.; Holman, R. R.; for the TECOS Study Group Tags: Emerging Science and Concepts for Management of Diabetes and Aging Source Type: research

Dipeptidyl Peptidase 4 Inhibition Stimulates Distal Tubular Natriuresis and Increases in Circulating SDF-1{alpha}1-67 in Patients With Type 2 Diabetes
CONCLUSIONS DPP-4 inhibition promotes a distal tubular natriuresis in conjunction with increased levels of intact SDF-1α1-67. Because of the distal location of the natriuretic effect, DPP-4 inhibition does not affect tubuloglomerular feedback or impair renal hemodynamic function, findings relevant to using DPP-4 inhibitors for treating type 2 diabetes.
Source: Diabetes Care - July 21, 2017 Category: Endocrinology Authors: Lovshin, J. A.; Rajasekeran, H.; Lytvyn, Y.; Lovblom, L. E.; Khan, S.; Alemu, R.; Locke, A.; Lai, V.; He, H.; Hittle, L.; Wang, W.; Drucker, D. J.; Cherney, D. Z. I. Tags: Complications-Nephropathy-Clinical and Translational Research Pathophysiology/Complications Source Type: research

Modelling incremental benefits on complications rates when targeting lower HbA1c levels in people with Type 2 diabetes and cardiovascular disease
ConclusionsThese simulated complication rates might help inform the degree to which complications might be reduced by targeting particular HbA1c reductions in Type 2 diabetes.This article is protected by copyright. All rights reserved.
Source: Diabetic Medicine - October 23, 2017 Category: Endocrinology Authors: S. A. Mostafa, R. L. Coleman, O. F. Agbaje, A. M. Gray, R. R. Holman, M. A. Bethel Tags: Research Article Source Type: research

Characteristics of Elderly Patients Initiating Sitagliptin or Non-DPP-4-Inhibitor Oral Antihyperglycemic Agents: Analysis of a Cross-Sectional US Claims Database
ConclusionPatients  ≥ 65 years with T2DM initiating sitagliptin tend to be older and have more comorbidities than those prescribed other classes of OAHA. Appropriate adjustment is required to minimize the impact of potential confounding and channeling bias in any comparative analyses including users of sitaglipti n.FundingMerck& Co., Inc., Kenilworth, NJ, USA.
Source: Diabetes Therapy - January 12, 2018 Category: Endocrinology Source Type: research

The kidney and cardiovascular outcome trials
Chronic kidney disease (CKD) affects a substantial minority of people with type 2 diabetes (T2D). Analysis of US National Health and Nutrition Examination Survey (NHANES) datasets from 2007 through 2012 showed Stage 3 or worse disease (estimated glomerular filtration rate [eGFR] <60 mL/min per 1.73 m2) in nearly one in five patients, with increasing age, blood pressure, obesity, and levels of glycemia all associated with higher likelihood of Stage 3 or worse CKD, comparable to findings from surveys from many other areas, which also show micro‐ or macroalbuminuria to be present in one‐sixth to one‐third of diab...
Source: Journal of Diabetes - January 19, 2018 Category: Endocrinology Authors: Zachary Bloomgarden Tags: Editorial Source Type: research